Who
Chris Nolet
Director
Company insider
Files Form 4 as: Director, ArriVent BioPharma; Director, Jasper Therapeutics; Director, Revance Therapeutics; Director, Polarityte; Director, Viela Bio.
In numbers
- Trades disclosed
- 33
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 16 Jul 2019
- Last trade
- 18 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 22 Jun 2026 | AVBP ArriVent BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,562 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | AVBP ArriVent BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,562 at $0.00 | filing |
| 3 Jul 2025filed 3 Jul 2025 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 18 Jun 2025filed 20 Jun 2025 | AVBP ArriVent BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,502 at $0.00 | filing |
| 6 Feb 2025filed 6 Feb 2025 | Revance Therapeutics | SEC FORM 4 Code D | —15,000 | filing |
| 4 Feb 2025filed 6 Feb 2025 | Revance Therapeutics | SEC FORM 4 Code U | $104K28,606 at $3.65 | filing |
| 6 Jun 2024filed 10 Jun 2024 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 1 May 2024filed 3 May 2024 | Revance Therapeuticsoption or derivative | SEC FORM 4 Code A | —23,458 at $0.00 | filing |
| 1 May 2024filed 3 May 2024 | Revance Therapeutics | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 25 Jan 2024filed 29 Jan 2024 | AVBP ArriVent BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,884 at $0.00 | filing |
| 7 Jun 2023filed 8 Jun 2023 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,000 at $0.00 | filing |
| 3 May 2023filed 5 May 2023 | Revance Therapeuticsoption or derivative | SEC FORM 4 Code A | —5,915 at $0.00 | filing |
| 3 May 2023filed 5 May 2023 | Revance Therapeutics | SEC FORM 4 Code A | —3,534 at $0.00 | filing |
| 12 Jan 2023filed 17 Jan 2023 | Polarityteoption or derivative | SEC FORM 4 Code M | —3,078 at $0.00 | filing |
| 12 Jan 2023filed 17 Jan 2023 | Polarityte | SEC FORM 4 Code M | —36,497 at $0.00 | filing |
| 12 Oct 2022filed 13 Oct 2022 | JSPR Jasper TherapeuticsBiotechnology | SEC FORM 4 Code A | —32,500 at $0.00 | filing |
| 1 Oct 2022filed 4 Oct 2022 | Polarityte | SEC FORM 4 Code A | —50,900 at $0.00 | filing |
| 4 May 2022filed 13 May 2022 | Revance Therapeuticsoption or derivative | SEC FORM 4 Code A | —10,756 at $0.00 | filing |
| 4 May 2022filed 6 May 2022 | Revance Therapeuticsoption or derivative | SEC FORM 4 Code A | —11,343 at $0.00 | filing |
| 4 May 2022filed 6 May 2022 | Revance Therapeutics | SEC FORM 4 Code A | —6,059 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.